Tatebe H - Search Results

1

Respiratory-gated proton beam therapy for intrahepatic cholangiocarcinoma without fiducial markers.

Okubo A, Matsumoto S, Tamamura H, Sato Y, Asahi S, Tatebe H, Yamamoto K, Matsushita K, Sasaki M, Maeda Y, Tameshige Y, Sunagozaka H, Aoyagi H, Shibata S, Takamatsu S, Kobayashi S. Okubo A, et al. Among authors: tatebe h. Radiat Oncol. 2024 Nov 13;19(1):160. doi: 10.1186/s13014-024-02550-2. Radiat Oncol. 2024. PMID: 39538328 Free PMC article.

2

Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry.

Harada H, Suefuji H, Mori K, Ishikawa H, Nakamura M, Tokumaru S, Murakami M, Ogino T, Iwata H, Tatebe H, Kubo N, Waki T, Yoshida D, Nakamura M, Hashimoto T, Araya M, Nakajima M, Nakayama H, Satouchi M, Shioyama Y. Harada H, et al. Among authors: tatebe h. Radiother Oncol. 2024 Sep;198:110385. doi: 10.1016/j.radonc.2024.110385. Epub 2024 Jun 18. Radiother Oncol. 2024. PMID: 38901770

3

Clinical results of proton beam radiotherapy for inoperable stage III non-small cell lung cancer: a Japanese national registry study.

Tatebe H, Harada H, Mori K, Iwata H, Akimoto T, Murakami M, Waki T, Ogino T, Nakamura M, Taguchi H, Nakayama H, Satouchi M, Aoyama H. Tatebe H, et al. J Radiat Res. 2023 Jun 16;64(Supplement_1):i8-i15. doi: 10.1093/jrr/rrad017. J Radiat Res. 2023. PMID: 37137157 Free PMC article.

4

Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer.

Harada H, Omori S, Mori K, Konno M, Murakami H, Imagumbai T, Fukuda H, Nakamatsu K, Kimura T, Tanabe H, Fujita H, Tatebe H, Fujitaka K, Nishimura Y. Harada H, et al. Among authors: tatebe h. Int J Clin Oncol. 2022 Jun;27(6):1025-1033. doi: 10.1007/s10147-022-02151-7. Epub 2022 Mar 19. Int J Clin Oncol. 2022. PMID: 35305192

5

Comprehensive analysis of Japanese nationwide cohort data of particle beam therapy for pulmonary, liver and lymph node oligometastases: particle beam therapy versus high-precision X-ray radiotherapy.

Aibe N, Ogino H, Wakatsuki M, Fujikawa K, Teramukai S, Fukumitsu N, Shiba S, Yamamoto N, Nomoto A, Ono T, Oguri M, Yamaguchi H, Numajiri H, Shibuya K, Okazaki S, Miyasaka Y, Okonogi N, Murata K, Tatebe H, Motegi A, Okimoto T, Yoshino T, Mandai M, Katoh N, Tsuji H, Sakurai H. Aibe N, et al. Among authors: tatebe h. J Radiat Res. 2023 Jun 16;64(Supplement_1):i69-i83. doi: 10.1093/jrr/rrad004. J Radiat Res. 2023. PMID: 37053162 Free PMC article.

6

Two-step Intensity-modulated Radiation Therapy for Oropharyngeal Cancer: Initial Clinical Experience and Validation of Clinical Staging.

Tatebe H, Doi H, Ishikawa K, Kawakami H, Yokokawa M, Nakamatsu K, Kanamori S, Shibata T, Kitano M, Nishimura Y. Tatebe H, et al. Anticancer Res. 2018 Feb;38(2):979-986. doi: 10.21873/anticanres.12312. Anticancer Res. 2018. PMID: 29374730

7

Multiple primary malignancies in patients with prostate cancer: increased risk of secondary malignancies after radiotherapy.

Okajima K, Ishikawa K, Matsuura T, Tatebe H, Fujiwara K, Hiroi K, Hasegawa H, Nishimura Y. Okajima K, et al. Among authors: tatebe h. Int J Clin Oncol. 2013 Dec;18(6):1078-84. doi: 10.1007/s10147-012-0496-3. Epub 2012 Nov 20. Int J Clin Oncol. 2013. PMID: 23179638

8

Neutrophil-to-Lymphocyte Ratio Predicts Survival After Whole-brain Radiotherapy in Non-small Cell Lung Cancer.

Doi H, Nakamatsu K, Anami S, Fukuda K, Inada M, Tatebe H, Ishikawa K, Kanamori S, Monzen H, Nishimura Y. Doi H, et al. Among authors: tatebe h. In Vivo. 2019 Jan-Feb;33(1):195-201. doi: 10.21873/invivo.11459. In Vivo. 2019. PMID: 30587623 Free PMC article.

9

Effect of oxygen pressure during incubation with a (10)B-carrier on (10)B uptake capacity of cultured p53 wild-type and mutated tumor cells: dependency on p53 status of tumor cells and types of (10)B-carriers.

Masunaga S, Tatebe H, Nishimura Y, Tano K, Sanada Y, Moriwaki T, Sakurai Y, Tanaka H, Suzuki M, Kondo N, Maruhashi A, Ono K. Masunaga S, et al. Among authors: tatebe h. Int J Radiat Biol. 2016;92(4):187-94. doi: 10.3109/09553002.2016.1137104. Epub 2016 Feb 18. Int J Radiat Biol. 2016. PMID: 26887694

10

Tumor Hypoxia Detected by ¹⁸F-fluoromisonidazole Positron Emission Tomography (FMISO PET) as a Prognostic Indicator of Radiotherapy (RT).

Tachibana I, Nishimura Y, Hanaoka K, Inada M, Fukuda K, Tatebe H, Ishikawa K, Nakamatsu K, Kanamori S, Hosono M. Tachibana I, et al. Among authors: tatebe h. Anticancer Res. 2018 Mar;38(3):1775-1781. doi: 10.21873/anticanres.12415. Anticancer Res. 2018. PMID: 29491116

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

95 results

Search Page

Filters